Eli Lilly's Retevmo Phase 3 LIBRETTO-432 Cuts Recurrence Risk 83% In RET+ Early-Stage NSCLC
31/5 14:26
(RTTNews) - Eli Lilly and Co. (LLY) announced results from the Phase 3 LIBRETTO-432 clinical trial of Retevmo (selpercatinib) as adjuvant therapy versus placebo in patients with early-stage (IB-IIIA) RET fusion-positive non-small cell lung cancer (NSCLC). The study met its primar...